Pandemics much like wars and other calamaties have a brighter side to them. They tend to bring the best of human ingenuity in terms of progress in science and technology in particular. Whilst the technology of mRNA wasn’t exactly developed during the pandemic, it did find its most important application saving millions of lives in the process. In this piece, Jaspreet Bindra, who tends to help us understand technology in layman terms in his column for the Mint, takes a stab at explaining the mRNA technology and its vast potential to work wonders with the human body.
“…DNA lives in the cell nucleus, but proteins are created in the cytoplasm, a totally different part of the cell. There had to be something that somehow carried DNA information to the protein factory. In 1961, French scientists Jacques Monod and François Jacob solved that puzzle by discovering mRNA, a specialised molecule that carried this source code of life, with the ‘m’ denoting its lowly status as a mere ‘messenger’.
If the covid pandemic is the greatest disruptor of our times, then mRNA vaccines are perhaps its greatest story. It is the story of fundamental, painstaking scientific research and struggle of 40 years, which blossomed into a planet-saving vaccine when its time came.
…As Adam Maida writes in The Atlantic, “The dream of mRNA persevered in part because its core principle was tantalizingly simple, even beautiful: The world’s most powerful drug factory might be inside all of us. People rely on proteins for just about every bodily function; mRNA tells our cells which proteins to make. With human-edited mRNA, we could theoretically commandeer our cellular machinery to make just about any protein under the sun.” You could make molecules to repair organs or direct blood flow, or you could commandeer your cells “to cook up an off-menu protein which our immune system would learn to identify as an invader and destroy.” That is what the mRNA wizards did in early 2020. On 11 January 2020, Chinese researchers published the genetic sequence of the ‘2019 novel coronavirus’. It took just 48 hours for Moderna to finalize the construct of its vaccine, and by February, it was shipped out for clinical trials.
That speed can be credited to the way mRNA vaccines work; it is like injecting a software code into our cells. The mRNA directs the cell to synthesize a protein, in this case the spike protein of the coronavirus, and the protein factory in the cell mass produces it. Our cells, in turn, kick their immune system into high gear, and start producing antibodies. Once this minute amount of injected mRNA is over, the cells stop making that protein, but the immune response persists—to seek and destroy the covid virus if it dares trespass again.
Thus, mRNA is an entirely different mechanism to build immunity; its story has just started. Scientists at Yale are close to a mRNA weapon against malaria. BioNTech is working on individualized proteins against particular tumours. Multiple sclerosis and other auto-immune diseases are also being targeted with tailored mRNA therapies. This is the beauty of this ‘genetic software code’; as Tureci says, “…mRNA can be broadly transformational. In principle, everything you can do with protein can be substituted by mRNA.”It is a great scientific breakthrough, but, like so many of them, this ‘overnight’ success took 40 years to happen, sparked in the 70s by the ‘mRNA hustler’ Katalin Kariko.”

 

If you want to read our other published material, please visit https://marcellus.in/blog/

Note: The above material is neither investment research, nor financial advice. Marcellus does not seek payment for or business from this publication in any shape or form. The information provided is intended for educational purposes only. Marcellus Investment Managers is regulated by the Securities and Exchange Board of India (SEBI) and is also an FME (Non-Retail) with the International Financial Services Centres Authority (IFSCA) as a provider of Portfolio Management Services. Additionally, Marcellus is also registered with US Securities and Exchange Commission (“US SEC”) as an Investment Advisor.



2024 © | All rights reserved.

Privacy Policy | Terms and Conditions